Skip to content

Ultrasound-guided Percutaneous Biliary Drainage Versus Endoscopic Ultrasound-guided Biliary Drainage

Prospective Multi-site Study of Ultrasound-guided Percutaneous Biliary Drainage and Endoscopic Ultrasound-guided Biliary Drainage With Implantation of a Self-expanding Metal Stent in Patients With Malignant, Distal Bile Duct Obstruction

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03546049
Acronym
PUMa
Enrollment
216
Registered
2018-06-06
Start date
2018-12-01
Completion date
2024-12-01
Last updated
2023-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bile Duct Obstruction, Extrahepatic

Keywords

ultrasound-guided percutaneous transhepatic biliary drainage, endoscopic ultrasound-guided antegrade biliary drainage, endoscopic ultrasound-guided transhepatic biliary drainage, endoscopic ultrasound-guided choledochal biliary drainage, self-expandable metal stent, malignant bile duct obstruction

Brief summary

Prospective multi-site study of ultrasound-guided percutaneous biliary drainage and endoscopic ultrasound-guided biliary drainage with implantation of a self-expanding metal stent in patients with malignant, distal bile duct obstruction (PUMa-study)

Detailed description

In a recent systematic review and meta-analysis about the efficacy and safety of endoscopic ultrasound-guided biliary drainage (EUBD) in comparison with percutaneous transhepatic biliary drainage (PTBD), there was no difference in technical success between the two procedures, but PTBD was associated with a lower level of clinical success, a higher level of post-procedural adverse events and a higher rate of re-interventions. The authors concluded that EUBD should be favored for biliary drainage when endoscopic retrograde cholangiopancreaticography (ERCP) failed or wasn´t possible to perform due to anatomical reasons. The hypothesis of this prospective multicenter study is that PTBD wasn´t performed in an appropriate way to compare it adequately with EUBD. The following improvements should be done. First, color Doppler ultrasound-guidance for cannulating the bile duct should be used in PTBD. The transgression of blood vessels with the risk of severe intrahepatic bleedings or hemobilia can be avoided, which are common adverse events in PTBDs when it is performed by fluoroscopic guidance. Second, the access to the bile duct from the left side of the liver should be favored. The access from the right liver side causes more adverse events such as biliary effusion or pneumothorax, as well as more patient discomfort and pain. Third, implantation of the self-expanding metal stent should be performed in the first session as a one-step procedure. This has the advantage that no further re-intervention is necessary after insertion of an external or an external/internal drainage, an outcome which can cause further adverse events such as bile duct leak along the catheter, biliary ascites or catheter dislocation. Fourth, stent release should be performed under endoscopic luminal guidance. In this way, the positioning and the correct expansion of the distal tip of the metal stent can be observed directly in comparison with the stent release which is only controlled by fluoroscopic guidance. On the other hand, EUBD should be performed in its best manner (special metal stents included) with the three techniques that are usually necessary to perform a successful EUBD: EUS-guided antegrade transpapillary drainage, EUS-guided transhepatic drainage and EUS-guided choledochal drainage. The study focuses on patients with malignant distal (infra-hilar) bile duct obstruction. It is presumed that the technical and clinical success rate is equal (non-inferiority) but the adverse event rate, the number of re-interventions and the number of days of hospitalization may differ between the two interventions. An adequate number of cases (106 patients in each intervention, drop outs included) should be recruited to calculate relevant statistical differences. Furthermore, patients will be followed over six months after the intervention to calculate an estimated survival analysis (with and without palliative chemotherapy).

Interventions

PROCEDUREUS-guided percutaneous biliary drainage

Device: metal stent. The self-expandable metal stent is implanted percutaneously by a transhepatic access route. The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed). Length: 6-10 cm. Diameter: 8-10 mm.

Device: metal stent. The transluminal (transgastric, transduodenal or transenteric) implanted self-expandable metal stent is released via echoendoscope. The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed) or mixed covered (one half covered, one half non-covered). The mixed covered stent is used for the transhepatic access. Length: 6-10 cm. Diameter: 8-10 mm.

Sponsors

University Hospital Heidelberg
CollaboratorOTHER
Theresienkrankenhaus und St. Hedwig-Klinik GmbH
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Intervention model description

prospective, non-randomized multicenter study (each center performs the intervention which can do best)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Inoperable, malignant disease with extrahepatic bile duct obstruction (infra- hilar) * ERCP was not successful or wasn´t possible due to anatomical reasons (for example status post-gastrectomy) * At least twofold elevated bilirubin level (\> 2mg/dl) * Histologically verified malignant disease * Abdominal ultrasound was performed * Computed tomography or magnetic resonance imaging of the abdomen was performed * A written consent was given

Exclusion criteria

* Relevant blood coagulation disorder (Quick \< 50%, Partial thromboplastin time \> 50 sec., thrombocytes \< 50/nl) * Extrahepatic cholangiocellular carcinoma (Klatskin tumor) Bismuth II-IV or intrahepatic cholangiocellular carcinoma * Operable, malignant disease or disease which can be cured by chemotherapy (for example aggressive Non Hodgkin-lymphoma) * Pregnancy or breastfeeding * Participation in another trial concerning PTBD or EUBD

Design outcomes

Primary

MeasureTime frameDescription
Technical success1 minute after injection of a radiocontrast agent into the expanded metal stentSuccessful implantation of a self-expanding metal stent to drain the obstructed bile duct, measured by the successful drainage of the radiocontrast agent by the metal stent

Secondary

MeasureTime frameDescription
Adverse eventsUp to 30 days after the interventionAll adverse events caused by the intervention
Re-interventions6 months after successful implantation of the metal stentNumber of re-interventions (PTBD or EUBD) that are necessary in the follow up (for example due to due stent occlusion or stent migration) after successful stent implantation
Clinical success7 days after the interventionDecrease of bilirubin level on more than a half of the initial value
Length of hospital stayThe day of the first PTBD or EUBD is counted as day 1 of hospital stay. The day of the discharge from the hospital is counted as the last day of hospital stay. An average 7 to 14 days is estimated.y.Length of hospital stay from the day of the first intervention (PTBD or EUBD) to the the day of discharge (days)
Survival timeFollow up of six monthsTime from the day of intervention to the death of the patient
Duration of the procedureThe day of the performed procedure (24 h), usually from 10 minutes up to 180 minutesDuration of biliary drainage procedure (US-guided percutaneous biliary drainage or EUS-guided biliary drainage) in minutes

Countries

Germany

Contacts

Primary ContactDaniel Schmitz, Dr.med.
d.schmitz@theresienkrankenhaus.de00496214245575
Backup ContactJochen Rudi, Prof.Dr.med.
j.rudi@theresienkrankenhaus.de00496214244631

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026